Skip to main content
Erschienen in: Uro-News 3/2017

04.03.2017 | Thrombotisch-thrombozytopenische Purpura | Zertifizierte Fortbildung

Nebenwirkungen bei onkologischer Behandlung

Wenn die Chemotherapie an die Niere geht

verfasst von: Maria Stavropoulou, Prof. Dr. med. Andreas Kribben, Anja Bienholz

Erschienen in: Uro-News | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Keine Wirkung ohne Nebenwirkung — dies gilt in besonderem Maße für die systemische Tumortherapie. Dank einer Reihe moderner antineoplastischer Therapiemöglichkeiten können immer mehr Patienten mit Krebserkrankung länger und auch bei guter Lebensqualität überleben. Voraussetzung dafür, ist aber für jeden einzelnen Krebspatienten die individuellen Risiken und die potenziellen Nebenwirkungen des infrage kommenden Chemotherapieprotokolls insbesondere im Hinblick auf die Nierenfunktion genau abzustimmen.
Literatur
1.
Zurück zum Zitat Bienholz A et al. From the nephrologist’s point of view: diversity of causes and clinical features of acute kidney injury. Clin Kidney J. 2015;8(4):405–14.CrossRefPubMedPubMedCentral Bienholz A et al. From the nephrologist’s point of view: diversity of causes and clinical features of acute kidney injury. Clin Kidney J. 2015;8(4):405–14.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Eljack ND et al. Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics. 2014;6(11):2126–33.CrossRefPubMed Eljack ND et al. Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics. 2014;6(11):2126–33.CrossRefPubMed
3.
Zurück zum Zitat Ishida S et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002;99(22):14298–302.CrossRefPubMedPubMedCentral Ishida S et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002;99(22):14298–302.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994–1007.CrossRefPubMed Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994–1007.CrossRefPubMed
5.
Zurück zum Zitat Oka T et al. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study. BMC Pharmacol Toxicol. 2014;15:70.CrossRefPubMedPubMedCentral Oka T et al. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study. BMC Pharmacol Toxicol. 2014;15:70.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Kidera Y et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One. 2014;9(7):e101902.CrossRefPubMedPubMedCentral Kidera Y et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One. 2014;9(7):e101902.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Santoso JT et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003;52(1):13–8.CrossRefPubMed Santoso JT et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003;52(1):13–8.CrossRefPubMed
8.
Zurück zum Zitat Muraki K et al. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. J Thorac Dis. 2012;4(6):562–8.PubMedPubMedCentral Muraki K et al. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. J Thorac Dis. 2012;4(6):562–8.PubMedPubMedCentral
9.
Zurück zum Zitat Morgan KP et al. Rates of renal toxicity in cancer patients receiving Cisplatin with and without Mannitol. Ann Pharmacother. 2014;48(7):863–9.CrossRefPubMed Morgan KP et al. Rates of renal toxicity in cancer patients receiving Cisplatin with and without Mannitol. Ann Pharmacother. 2014;48(7):863–9.CrossRefPubMed
10.
Zurück zum Zitat Xia L et al. Comparison of cochlear cell death caused by cisplatin, alone and in combination with furosemide. Toxicol Pathol. 2014;42(2):376–85.CrossRefPubMed Xia L et al. Comparison of cochlear cell death caused by cisplatin, alone and in combination with furosemide. Toxicol Pathol. 2014;42(2):376–85.CrossRefPubMed
11.
12.
Zurück zum Zitat Choi JH et al. Successful treatment of cisplatin overdose with plasma exchange. Yonsei Med J. 2002;43(1):128–32.CrossRefPubMed Choi JH et al. Successful treatment of cisplatin overdose with plasma exchange. Yonsei Med J. 2002;43(1):128–32.CrossRefPubMed
13.
Zurück zum Zitat Oguri T et al. Extension of the Calvert formula to patients with severe renal insufficiency. Cancer Chemother Pharmacol. 2015;76(1):53–9.CrossRefPubMed Oguri T et al. Extension of the Calvert formula to patients with severe renal insufficiency. Cancer Chemother Pharmacol. 2015;76(1):53–9.CrossRefPubMed
14.
Zurück zum Zitat Oguri T et al. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Cancer Chemother Pharmacol. 2010;66(4):813–7.CrossRefPubMed Oguri T et al. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Cancer Chemother Pharmacol. 2010;66(4):813–7.CrossRefPubMed
15.
Zurück zum Zitat Guddati AK et al. Dose adjustment of carboplatin in patients on peritoneal dialysis. Med Oncol. 2014;31(5):946.CrossRefPubMed Guddati AK et al. Dose adjustment of carboplatin in patients on peritoneal dialysis. Med Oncol. 2014;31(5):946.CrossRefPubMed
16.
Zurück zum Zitat El-Sisi AD et al. Protective effects of alpha lipoic acid versus N-acetylcysteine on ifosfamide-induced nephrotoxicity. Toxicol Ind Health. 2015;31(2):97–107.CrossRef El-Sisi AD et al. Protective effects of alpha lipoic acid versus N-acetylcysteine on ifosfamide-induced nephrotoxicity. Toxicol Ind Health. 2015;31(2):97–107.CrossRef
17.
Zurück zum Zitat Hanly L et al. Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. Expert Opin Drug Saf. 2009;8(2):155–68.CrossRefPubMed Hanly L et al. Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. Expert Opin Drug Saf. 2009;8(2):155–68.CrossRefPubMed
19.
Zurück zum Zitat Hanly L et al. The Effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model. Anticancer Res. 2012;32(9):3791–8.PubMed Hanly L et al. The Effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model. Anticancer Res. 2012;32(9):3791–8.PubMed
20.
Zurück zum Zitat Wiczer Tet al. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract. 2016;22(3):430–6.CrossRefPubMed Wiczer Tet al. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract. 2016;22(3):430–6.CrossRefPubMed
21.
Zurück zum Zitat Liu WC et al. Clinical dilemma over low-dose methotrexate therapy in dialysis patients: a case report and review of literature. Iran J Kidney Dis. 2014;8(1):81–4.PubMed Liu WC et al. Clinical dilemma over low-dose methotrexate therapy in dialysis patients: a case report and review of literature. Iran J Kidney Dis. 2014;8(1):81–4.PubMed
22.
Zurück zum Zitat Mura S et al. Lipid prodrug nanocarriers in cancer therapy. J Control Release. 2015;208:25–41.CrossRefPubMed Mura S et al. Lipid prodrug nanocarriers in cancer therapy. J Control Release. 2015;208:25–41.CrossRefPubMed
23.
Zurück zum Zitat Izzedine H et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006;21(11):3038–45.CrossRefPubMed Izzedine H et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006;21(11):3038–45.CrossRefPubMed
24.
Zurück zum Zitat Elliott MA, Nichols WL. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Mayo Clin Proc. 2001;76(11):1154–62.CrossRefPubMed Elliott MA, Nichols WL. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Mayo Clin Proc. 2001;76(11):1154–62.CrossRefPubMed
25.
Zurück zum Zitat Izzedine H, Perazella MA. Thrombotic Microangiopathy, Cancer, and Cancer Drugs. Am J Kidney Dis. 2015;66(5): 857–68.CrossRefPubMed Izzedine H, Perazella MA. Thrombotic Microangiopathy, Cancer, and Cancer Drugs. Am J Kidney Dis. 2015;66(5): 857–68.CrossRefPubMed
26.
Zurück zum Zitat Kasper S et al. Protein A immunoadsorption therapy for refractory, mitomycin C-associated thrombotic microangiopathy. Transfusion. 2007;47(7):1263–7.CrossRefPubMed Kasper S et al. Protein A immunoadsorption therapy for refractory, mitomycin C-associated thrombotic microangiopathy. Transfusion. 2007;47(7):1263–7.CrossRefPubMed
27.
Zurück zum Zitat Gilbert RD et al. Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of treated with eculizumab. Clin Kidney J. 2013;6(4):421–5.CrossRefPubMedPubMedCentral Gilbert RD et al. Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of treated with eculizumab. Clin Kidney J. 2013;6(4):421–5.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Humphreys BD et al. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004;100(12):2664–70.CrossRefPubMed Humphreys BD et al. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004;100(12):2664–70.CrossRefPubMed
30.
Zurück zum Zitat Lee HW et al. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature. Gut Liver. 2014;8(1):109–12.CrossRefPubMedPubMedCentral Lee HW et al. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature. Gut Liver. 2014;8(1):109–12.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Bharthuar A et al. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer Chemother Pharmacol. 2009;64(1):177–81.CrossRefPubMed Bharthuar A et al. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer Chemother Pharmacol. 2009;64(1):177–81.CrossRefPubMed
32.
Zurück zum Zitat Murakami N et al. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9(3):411–7.CrossRefPubMedPubMedCentral Murakami N et al. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9(3):411–7.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Cortazar FB et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–47.CrossRefPubMed Cortazar FB et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–47.CrossRefPubMed
Metadaten
Titel
Nebenwirkungen bei onkologischer Behandlung
Wenn die Chemotherapie an die Niere geht
verfasst von
Maria Stavropoulou
Prof. Dr. med. Andreas Kribben
Anja Bienholz
Publikationsdatum
04.03.2017
Verlag
Springer Medizin
Erschienen in
Uro-News / Ausgabe 3/2017
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI
https://doi.org/10.1007/s00092-017-1285-0

Weitere Artikel der Ausgabe 3/2017

Uro-News 3/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.